Special Issue "PD-L1, A Master Regulator of Immunity"
Deadline for manuscript submissions: closed (31 July 2019) | Viewed by 37655
Receptor programmed cell death-1 (PD-1) is a co-inhibitory receptor that is mainly expressed on activated T cells. Through binding with its ligand, programmed death ligand-1 (PD-L1), PD-1 regulates the activity of T cells. As such, adaptive immune responses mediated by T cells against invading pathogens are strictly regulated, thereby avoiding collateral damage to the host. This regulatory circuit is however abused in several diseases such as chronic infection and cancer to dampen immune responses prematurely. Blocking the PD-1:PD-L1 immune checkpoint axis has therefore garnered substantial interest. In cancer, PD-1:PD-L1 blockade has resulted in unprecedented successes in individual patients across a variety of cancer types. However, a large cohort of patients fails to respond to PD-1:PD-L1 blockade. Insights into different mechanisms underlying this therapy failure are gradually gained. These highlight the complexity of the immune system and cancer as a disease. They further shed light on how combination with other therapies could enhance the response rates to PD-1:PD-L1 blockade.
Prof. Karine Breckpot
Dr. David Escors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- T cell
- Immune checkpoint
- Myeloid cell
- Infectious disease